Shah et al. investigated CD19 CAR T-cell therapy in children and young adults (CAYAs) with relapsed or refractory B-ALL and found that, among 50 patients, 62% achieved complete remission, with 90.3% being MRD-negative [47]. Here, CD19 is linked to acute lymphoblastic leukemia.